Detailed FundamentalsSingle-page fundamentals layout — broad valuation, growth, profitability, health, competitors, top funds & analyst detail.
Price chartUnavailable
Loading price history...
52-Week Range
Trailing twelve months
$10.15$21.02
1-Month Range
Month up 21.4%
$17.25$20.95
Daily Price Range
Day up 0.5%
$20.60$21.02
Volume
vs 9M avg
8M9M avg
Profile
Identity and capital structure
SectorUnclassified
IndustryCommon Stock
Market Cap$24.0B
Short % of Float—
Employees—
Sales$14,300M
Shares Outstanding1,146,454,729
IPO Date—
Last Reported Qtr.—
Next Qtr. Report—
Headquarters—
Homepagewww.vtrs.com
Viatris Inc — Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabo….· via yahoo
Warnings
3 signals
Live
- ROE below 5% (-4.2%)
- Negative revenue growth (-0.3%)
- Price 106% above 52-week low — momentum stretched
Scores
0–100 · higher is better except where noted · Insider Sent: directional buy ratio (excl. gifts/grants)
Value
95
Growth
30
Quality
30
Sentiment
95
Insider Sent.
—
Piotroski F
7
Altman Z
0.9
Consensus rating unavailable — no analyst coverage on file for VTRS.
Price targets unavailable — no 12-month targets on file for VTRS.
Valuation Engine
DCF Intrinsic Valuation Model
Run an interactive 5-year Discounted Cash Flow valuation on VTRS, calculate Margin of Safety, and stress-test WACC discount hurdles.
RetrievedQuote: Live · Insiders: Live · Fundamentals/Benchmarks: Curated · Vantage Composite · 3 warnings surfacedNov 11, 2026, 6:08 PM UTC